drugset

drugset / Trial / NCT06050694

Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL)

NCT06050694 ↗

Phase 2 Recruiting 40 enrolled University Health Network, Toronto

Non-randomizedSequentialOpen-labelOther

Summary

This is a phase ll study of participants with untreated diffuse large B Cell lymphoma (DLBCL).

Timeline

Start: 2025-01-24
Primary completion: 2027-11
Completion: 2027-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Glofitamab	Monoclonal antibody	10 mg	—

Indications